Vamil Divan
Stock Analyst at Guggenheim
(4.82)
# 93
Out of 5,134 analysts
248
Total ratings
69.83%
Success rate
20.82%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Buy | $122 → $140 | $121.57 | +15.16% | 15 | Feb 6, 2026 | |
| AMGN Amgen | Maintains: Neutral | $305 → $347 | $373.36 | -7.06% | 2 | Feb 6, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $227 → $240 | $243.33 | -1.37% | 19 | Jan 23, 2026 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $115 → $124 | $78.90 | +57.16% | 14 | Jan 16, 2026 | |
| INSM Insmed | Maintains: Buy | $230 → $221 | $150.52 | +46.82% | 8 | Dec 18, 2025 | |
| PFE Pfizer | Maintains: Buy | $33 → $35 | $27.37 | +27.88% | 23 | Nov 24, 2025 | |
| JBIO Jade Biosciences | Maintains: Buy | $14 → $17 | $13.91 | +22.26% | 2 | Nov 18, 2025 | |
| ELDN Eledon Pharmaceuticals | Maintains: Buy | $9 → $8 | $2.11 | +279.15% | 1 | Nov 18, 2025 | |
| SCYX SCYNEXIS | Maintains: Buy | $4 → $3 | $0.76 | +294.74% | 3 | Oct 28, 2025 | |
| ABBV AbbVie | Maintains: Buy | $227 → $242 | $232.86 | +3.93% | 28 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $11 | $5.73 | +91.97% | 2 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $13 | $10.77 | +20.70% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $39 | $27.82 | +40.19% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $7 | $2.02 | +246.53% | 2 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $6.22 | +864.63% | 1 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $47 | $28.75 | +63.48% | 8 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.66 | +275.94% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $42.85 | +42.36% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $16.52 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $3.64 | +614.29% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.15 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $22.95 | -17.21% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $127.76 | -23.29% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $32.90 | +3.34% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.96 | +237.84% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $183.30 | -73.27% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $1,036.05 | -65.64% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $6.91 | -13.17% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $11.48 | +1,241.46% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $4.39 | +241.69% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $33.93 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $34.41 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $17.49 | -14.24% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $60.35 | +1.08% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $3.55 | +2,801.41% | 3 | Jan 17, 2018 |
Merck & Co.
Feb 6, 2026
Maintains: Buy
Price Target: $122 → $140
Current: $121.57
Upside: +15.16%
Amgen
Feb 6, 2026
Maintains: Neutral
Price Target: $305 → $347
Current: $373.36
Upside: -7.06%
Johnson & Johnson
Jan 23, 2026
Maintains: Buy
Price Target: $227 → $240
Current: $243.33
Upside: -1.37%
ANI Pharmaceuticals
Jan 16, 2026
Maintains: Buy
Price Target: $115 → $124
Current: $78.90
Upside: +57.16%
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $230 → $221
Current: $150.52
Upside: +46.82%
Pfizer
Nov 24, 2025
Maintains: Buy
Price Target: $33 → $35
Current: $27.37
Upside: +27.88%
Jade Biosciences
Nov 18, 2025
Maintains: Buy
Price Target: $14 → $17
Current: $13.91
Upside: +22.26%
Eledon Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.11
Upside: +279.15%
SCYNEXIS
Oct 28, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.76
Upside: +294.74%
AbbVie
Oct 20, 2025
Maintains: Buy
Price Target: $227 → $242
Current: $232.86
Upside: +3.93%
Sep 9, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $5.73
Upside: +91.97%
Sep 8, 2025
Maintains: Buy
Price Target: $14 → $13
Current: $10.77
Upside: +20.70%
Sep 8, 2025
Maintains: Buy
Price Target: $31 → $39
Current: $27.82
Upside: +40.19%
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $2.02
Upside: +246.53%
Apr 21, 2025
Initiates: Buy
Price Target: $60
Current: $6.22
Upside: +864.63%
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $28.75
Upside: +63.48%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $2.66
Upside: +275.94%
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $42.85
Upside: +42.36%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $16.52
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $3.64
Upside: +614.29%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $2.15
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $22.95
Upside: -17.21%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $127.76
Upside: -23.29%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $32.90
Upside: +3.34%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $2.96
Upside: +237.84%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $183.30
Upside: -73.27%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $1,036.05
Upside: -65.64%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $6.91
Upside: -13.17%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $11.48
Upside: +1,241.46%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $4.39
Upside: +241.69%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $33.93
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $34.41
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $17.49
Upside: -14.24%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $60.35
Upside: +1.08%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $3.55
Upside: +2,801.41%